Research programme : skin disorders therapeutics - Chemiderm/Harvard
Latest Information Update: 28 Dec 2019
Price :
$50 *
At a glance
- Originator Chemiderm Inc
- Developer Chemiderm Inc; Harvard University
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis; Psoriasis
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for research development in Atopic-dermatitis in USA (Topical)
- 28 Dec 2019 No recent reports of development identified for research development in Psoriasis in USA (Topical)
- 19 Nov 2015 Chemiderm and Harvard University agree to develop compounds for Psoriasis and Atopic dermatitis in USA